Related Experiment Video

Updated: Aug 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer

Martin Gleave1, Colleen Nelson, Kim Chi

  • 1The Prostate Centre at Vancouver General Hospital, Division of Urology, University of British Columbia, D9, 2733 Heather Street, Vancouver, BC, Canada V6H 3Z3. gleave@interchange.ubc.ca

Current Drug Targets
|March 20, 2003
PubMed

Insights

New antisense oligonucleotides offer targeted therapy for advanced prostate cancer, potentially preventing progression to androgen independence. This approach shows promise for improved cancer treatment regimens.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced prostate cancer survival is limited by progression to androgen independence.
  • Novel therapeutic agents are needed to prevent this lethal stage.
  • Targeting cancer-specific molecular pathways is a key strategy for new anti-cancer drugs.

Purpose of the Study:

  • To review the potential of antisense oligonucleotides as a new therapeutic strategy for advanced prostate cancer.
  • To discuss the status of antisense targeting for key genes involved in prostate cancer progression.

Main Methods:

  • Review of current literature on antisense oligonucleotide technology.
  • Analysis of antisense targeting strategies for specific genes (bcl-2, bcl-xL, clusterin, androgen receptor, IGFBPs).

Main Results:

  • Antisense oligonucleotides demonstrate high specificity for cancer cells.
  • They offer a potentially favorable side-effect profile due to targeted action.
  • Emerging clinical data suggest antisense oligonucleotides could be integral to future cancer therapies.

Conclusions:

  • Antisense oligonucleotides represent a promising therapeutic modality for advanced prostate cancer.
  • Targeting specific genes involved in androgen independence is a viable strategy.
  • Further clinical development is warranted to realize the full potential of this approach.

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 18, 2019

Related Concept Videos

Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...